Skip to main content
. 2015 May 18;10(1):255–259. doi: 10.3892/ol.2015.3216

Figure 1.

Figure 1.

Kaplan-Meier analysis indicating a significant difference in biochemical progression-free survival depending on the duration of ADT (P=0.04). The five-year biochemical progression-free survival rates in patients treated with <36 or ≥36 months of ADT were 84.0% [95% confidence interval (CI), 58.0–94.6] and 96.2% (95% CI, 90.2–98.6), respectively. ADT, androgen deprivation therapy.